ReviewCurrent HIV/AIDS reports2019
Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals.
Review in Current HIV/AIDS reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035.Journal of the International AIDS Society · 2024Trial
- A latent trajectory analysis of young sexual and gender minorities' adherence to three rectal microbicide placebo formulations (MTN-035; a randomized crossover trial).BMC public health · 2023Trial
- Trial
- Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial.The American journal of psychiatry · 2022Trial
- Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.The lancet. HIV · 2021Trial
- Family-Based Discrimination, Non-disclosure of Sexual Orientation or Gender identity, and Initiation of Oral Pre-exposure Prophylaxis Among Adolescents.AIDS and behavior · 2026Article
- Product Nkabinde Mediates Cytokine Modulation and Antiviral Activity in HIV-Infected MT4 Cells.International journal of molecular sciences · 2026Article
- Methamphetamine use and HIV prevention: a qualitative study on challenges and opportunities for PrEP utilization.AIDS care · 2026Article
- Healthcare workers' perspectives on HIV pre-exposure prophylaxis delivery in Sub-Saharan Africa: implications for injectable formulation rollout-a narrative review.Frontiers in public health · 2026Review
- Article
- Medical Mistrust and Willingness to Use Long-Acting PrEP Among Black and Hispanic/Latino MSM.AIDS and behavior · 2025Article
- Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Minority adolescents' HIV PrEP awareness and preferences in Alabama.BMC research notes · 2025Article
- PrEP Navigator Perceptions of the Implementation of Injectable PrEP on HIV Prevention in Tennessee.International journal of environmental research and public health · 2025Article
- Adolescent Youth Survey on HIV Prevention and Sexual Health Education in Alabama: Protocol for a Web-Based Survey With Fraud Protection Study.JMIR research protocols · 2025Article
- Claims-Based Algorithm to Identify Pre-Exposure Prophylaxis Indications for Tenofovir Disoproxil Fumarate and Emtricitabine Prescriptions (2012-2014): Validation Study.JMIR formative research · 2024Article
- Health intervention trials involving transgender, transabled and transracial persons in Africa: A scoping review.Public health challenges · 2024Review
- HIV pre-exposure prophylaxis programme preferences among sexually active HIV-negative transgender and gender diverse adults in the United States: a conjoint analysis.Journal of the International AIDS Society · 2024Article
- Using Motivational Interviewing to Increase HIV PrEP Initiation and Adherence: a Scoping Review.Prevention science : the official journal of the Society for Prevention Research · 2023Article
- Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey.Journal of the International AIDS Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewPre-exposure prophylaxis (PrEP) is a potent HIV prevention strategy, but uptake of daily oral PrEP remains low. This review covers PrEP agents currently available and agents and modalities under investigation. RECENT
findingsInjectable ARV preparations have high acceptability among users but are likely to require adherence to 8-week interval injections. Topical microbicide gels and vaginal rings have underperformed by intention-to-treat analyses in efficacy studies, at least in large part due to challenges with adherence and/or sustained use. However, daily oral TDF-FTC also underperformed in randomized, placebo-controlled trials compared to expectations and subsequent real-world pragmatic use. On-demand (2-1-1 dosing strategy for MSM) and injectable PrEP appear to be acceptable among participants in clinical trials. These modalities are particularly compelling alternatives for individuals who either do not want to take a daily medication (both on-demand and injectable) and/or want to take PrEP without a long commitment (on-demand). Emerging modalities such as vaginal films, microneedles, and subdermal implants have numerous advantages but are still in early stages of development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.